

## STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES Bureau for Medical Services

Sherri A. Young, DO, MBA, FAAFP Interim Cabinet Secretary

## Agenda Drug Utilization Review Board Meeting (3<sup>rd</sup> Quarter) September 20<sup>th</sup>, 2023 Location: VIRTUAL only

Time: 4:00 - 6:00 p.m.

Cynthia E. Beane, MSW, LCSW Commissioner

I. Call to order/ Introductions:

Call-in information: 1-786-581-6667 PIN: 103 843 101#

- II. Approval of Minutes from May 24th, 2023 DUR Meeting
- III. Old Business
- IV. New Business

## A. Speakers

Public comments for this meeting will only be accepted in writing. Comments need to be sent via email to Priya Shah (Priya.B.Shah@wv.gov) and Doug Sorvig (Richard.D.Sorvig@wv.gov) no later than **September 19**<sup>th</sup>, **2023**. Comments will be posted on the BMS website under DUR Board Meetings for public review.

Representatives of drug manufacturers being presented at DUR Board can register to be on hand to answer any questions put forth by DUR board members. Registrants must provide a name, email address, name of drug and company they are representing, and provide a completed disclosure form to the email address above no later than **September 19**<sup>th</sup>, **2023**.

- B. Updates from August 23<sup>rd</sup>, 2023 P&T Committee Meeting
- C. Proposed Prior-Authorization Criteria:
  - 1. Atorvaliq
  - 2. Hereditary Angioedema agents (treatment)- Berinert
  - 3. Hereditary Angioedema agents (prophylaxis)
  - 4. Ligrev
  - 5. Zavzpret Nasal Spray
  - 6. Vowst
  - 7. Synagis
- V. Reports 2<sup>nd</sup> Quarter 2023
  - A. Gainwell Technologies
  - B. Rational Drug Therapy Program
  - C. Kepro
- VI. Other Business

  Next Meeting and Adjournment November 15<sup>th</sup> 2023, virtually.